TABLE 1

Human Dosimetry for ¹⁸F-FNP-59 (n = 4; 2 Men, 2 Women), Compared with Rodent-Derived Human Estimated ¹⁸F-FNP-59, Human ¹³¹I-NP-59, and Human ¹⁸F-FDG

	Human sex average dose
Target organ	mSv/MBq	±95% error, mSv/MBq	Rodent sex average dose (mSv/MBq)	Human ¹³¹I-NP59* average dose (mSv/MBq)	¹⁸F-FDG^† average dose (mSv/MBq)
Adrenals	2.72E–02	6.82E–03	6.82E–02	4.0E+00	1.3E–02
Brain	7.92E–03	1.41E–03	3.70E–03		1.9E–02
Breasts	8.43E–03	1.12E–02	1.17E–02	4.0E–01	9.2E–03
Esophagus	1.43E–02	1.90E–03	1.43E–02
Eyes	7.94E–03	1.42E–03	5.22E–03
Gallbladder wall	3.09E–01	3.73E–01	2.11E–02		1.3E–02
Left colon	1.40E–02	3.91E–03	2.85E–02
Small intestine	1.34E–02	3.71E–03	5.14E–02	4.1E–01	1.3E–02
Stomach wall	1.48E–02	3.18E–03	1.57E–02	4.0E–01	1.3E–02
Right colon	1.88E–02	9.58E–03	5.76E–02
Rectum	1.07E–02	2.09E–03	1.65E–02
Heart wall	1.10E–02	3.02E–03	1.60E–02		5.9E–02
Kidneys	1.91E–02	9.46E–03	1.51E–02	4.1E–01	2.0E–02
Liver	7.29E–02	7.70E–03	3.45E–02	1.2E+00	1.6E–02
Lungs	2.19E–02	8.57E–03	2.44E–02		1.7E–02
Ovaries	1.06E–02	1.72E–02	3.11E–02	3.8E–01	1.4E–02
Pancreas	1.91E–02	1.01E–02	1.68E–02	4.3E–01	2.6E–02
Prostate	1.69E–02	1.08E–02	1.32E–02
Salivary glands	8.90E–03	1.95E–03	1.10E–02
Red marrow	1.07E–02	2.14E–03	1.22E–02	3.9E–01	1.3E–02
Osteogenic cells	1.66E–02	5.59E–03	1.04E–02	3.7E–01
Spleen	5.75E–02	7.92E–02	3.36E–02	3.9E–01	3.8E–02
Testes	9.99E–03	2.94E–02	6.02E–03	3.6E–01	1.1E–02
Thymus	1.16E–02	2.16E–03	1.40E–02		1.2E–02
Thyroid	1.01E–02	2.38E–03	1.25E–02	3.0E+01	1.1E–02
Urinary bladder wall	1.11E–02	5.23E–03	1.32E–02	3.9E–01	8.6E–02
Uterus	1.03E–02	1.63E–02	1.54E–02	4.0E–01	1.7E–02
Total body	1.20E–02	2.08E–03	1.36E–02
Effective dose	1.75E–02	5.33E–03	1.92E–02	5.6E+01

* ICRP 53 (44).
^†FDA product insert (45).
Significant decreased dose, 2 orders of magnitude, is seen with ¹⁸F-FNP-59 compared with ¹³¹I-NP-59.